University Innovation Cluster
Innovation facilitator

From UM labs to Abivax: the fabulous destiny of the drug that sought to treat chronic intestinal diseases

Published on in News

Collaboration between the laboratories of the University of Montpellier (UM) and Abivax has given rise to the treatment Obefazimod: the fruit of almost twenty years of R&D, this molecule could revolutionize the management of chronic intestinal diseases. A national and international success story, the fruit of collaboration between Montpellier research and an innovative company.

Read the full article: From UM labs to Abivax: the fabulous destiny of the drug that sought to treat chronic intestinal diseases